AstraZeneca AZN announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with d
https://www.nasdaq.com/articles/astrazeneca-inks-agreement-boost-cardiovascular-pipeline